HC Wainwright restated their buy rating on shares of Femasys (NASDAQ:FEMY – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. The firm currently has a $12.00 price objective on the stock.
Separately, Chardan Capital decreased their price target on shares of Femasys from $12.00 to $10.00 and set a buy rating on the stock in a report on Wednesday, August 14th.
Check Out Our Latest Report on FEMY
Femasys Stock Performance
Femasys (NASDAQ:FEMY – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.50 million. Femasys had a negative return on equity of 119.97% and a negative net margin of 1,757.16%. Analysts predict that Femasys will post -0.79 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Femasys
A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC lifted its holdings in shares of Femasys Inc. (NASDAQ:FEMY – Free Report) by 30.6% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 309,274 shares of the company’s stock after purchasing an additional 72,505 shares during the period. Clear Creek Financial Management LLC owned about 1.40% of Femasys worth $479,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 65.27% of the company’s stock.
About Femasys
Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.
Featured Articles
- Five stocks we like better than Femasys
- What Are Dividend Contenders? Investing in Dividend Contenders
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How is Compound Interest Calculated?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.